European Archives - Page 250 of 1060 - European Medical Journal

Review of the 2024 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO)

The 24th edition of the annual World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO) took place this year in London, UK, from the 11th–14th of April…

Brachytherapy for Prostate Cancer Linked to Higher Risk of Second Malignancy

A retrospective review reveals brachytherapy may elevate long-term pelvic second malignancy risk compared to radical prostatectomy, urging continued screening and education.

New Screening Protocol Detects Aggressive Prostate Cancer

The ProScreen trial introduces a three-step prostate cancer screening method, offering potential to detect aggressive cancers while reducing unnecessary diagnoses. Read more.

Optimising Teriparatide Use in Osteoporosis

Dr Enrique Casado and Professor Lothar Seefried talk about the of early identification of individuals at risk of osteoporosis fractures…

Screening Snag: Limitations of Questionnaire-Based Osteoporosis Screening

Self-administered questionnaires as screening tools for osteoporosis are not sufficient for systematic screening due to low and differential screening uptake…

OA-07 Trial: Lorecivivint's Role in Knee Osteoarthritis Management

Findings from the Phase III trial, OA-07, were presented at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases 2024…

Hip Fracture Occurrence Declines With Age

New research presented at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases focused on the occurrence of hip fracture in different age groups…

Does pharma have the power to turn back time?

Finding a way to combat the negative effects of ageing could save healthcare systems millions. Learn whether ageing could be the next big pharma market to take the world by storm.

EMJ

Retraction: Building on a Strong Foundation to Address a New Era to Help Protect Against Pneumococcal Disease

This article on building on a strong foundation to address a new era to help protect again has been retracted.

Orphan drugs face new pressures

The orphan drug market has seen robust growth over the past decade, but may face challenges in maintaining its trajectory due to evolving investor and payer preferences.